Business
Spectral AI Announces 2026 First Quarter Financial Results
Development Work for DeepView® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA Reiterates Annual Revenues Guidance DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2026. “Our results for the 2026 firs
About this update from Spectral Ai, Inc.
[{"type":"image","alt":"Spectral AI, Inc.","displaySize":"","headline":null,"caption":"Spectral AI, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":64,"url":"https://media.zenfs.com/en/globenewswire.com/915f0e1842fac94f00f8d678be38c737"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/o6ut9f3Y4I5YRiYZrkvZzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/915f0e1842fac94f00f8d678be38c737","width":300,"height":64},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/o6ut9f3Y4I5YRiYZrkvZzg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTkwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/915f0e1842fac94f00f8d678be38c737","width":300,"height":64}},"lazy":false},{"type":"text","content":"Development Work for DeepView® Systems Continues with Support of Recently Awarded $31.7 Million of Funding from BARDA","length":118,"tagName":"p"},{"type":"text","content":"Reiterates Annual Revenues Guidance ","length":35,"tagName":"p"},{"type":"text","content":"DALLAS, May 12, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the first quarter ended March 31, 2026.","length":315,"tagName":"p"},{"type":"text","content":"“Our results for the 2026 first quarter reflected the progress we have made in developing our DeepView® System for burn indication under the base phase of our Project BioShield Contract with BARDA,” said Vincent Capone, Chief Executive Officer of Spectral AI. “The work we have completed under this base phase – which was ongoing in last year’s first quarter - allowed us to submit our De Novo 510(k) application to the U.S. Food and Drug Administration (“FDA”) for the DeepView System in June 2025. As we await determination on market authorization from the FDA, we are furthering the development of the DeepView System under an accelerated second phase of our contract with BARDA that includes $31.7 million of advanced, non-dilutive funding.”","length":745,"tagName":"p"},{"type":"text","content":"Mr. Capone concluded, “Our financial condition remains strong, and we continue to make investments that align with our strategic priorities and in advance of planned commercializ...